Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib

Agios Pharmaceuticals (NASDAQ:AGIO) has secured exclusive global rights to cevidoplenib, a next-generation oral SYK inhibitor ...
Medical Xpress

One inhibitor, opposite outcome: How a double-target effect could reshape ferroptosis therapies

Switching off an enzyme that plays an important role in sugar metabolism, glycolysis, would normally be expected to cause serious problems for cells. Surprisingly, the opposite is also true: Cells can ...

Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer

Key milestone positions ART6043 as the most advanced Pol-theta inhibitor in clinical development; the potentially first-in-class program is ...

Tata-backed Impetis licenses JAK inhibitor assets to Vyome Holdings

Deal gives Vyome entry into the fast-growing market for next-generation autoimmune and inflammatory disease drugs ...
EurekAlert!

Nature Biotechnology | Generative chemistry enables Insilico to develop gut-restricted PhD inhibitors promising for intestinal mucosal barrier repair and immunomodulation

The study, published in Nature Biotechnology, highlights the role of Chemistry42 and its submodules in supporting drug candidate design and optimization. The research underscores the potential of ...
C&EN

Kinase inhibitors can be targeted protein degraders too

An illustration shows the structure of an inhibitor bound to the active site of membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase. An inhibitor bound to the active site of ...